Login
Companies $ZNTL
$1.63 +$0.03 (1.87%) After hours
Zentalis Pharmaceuticals, Inc. logo

Zentalis Pharmaceuticals, Inc.

zentalis.com

What Do They Do?

Develops an investigational cancer medicine for patients with ovarian cancer and other cancers.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −8% (Loss)
vs −$26.7M in Q3 FY2025

A narrower development focus The older report described several drug candidates, discovery programs and studies across a range of cancers. The latest report centers development on azenosertib, focused on platinum-resistant ovarian cancer, with other tumor types as further opportunities.

Who Do They Compete With?

Competes with Debiopharm Research & Manufacturing, Bristol-Myers Squibb, Aprea Therapeutics, Schrödinger, Acrivon Therapeutics, Impact Therapeutics, Shouyao Holdings, WuXi AppTec, and Wigen Biomedicine Technology (Shanghai)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support